These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 141049)

  • 1. Murine leukemia growth inhibition or enhancement following immunization with tumor cells antigenically altered by drug treatment.
    Riccardi C; Giampietri A; Puccetti P; Biancifiori F; Fioretti MC
    Pharmacol Res Commun; 1977 Apr; 9(4):349-58. PubMed ID: 141049
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-mediated changes of tumour cell immunogenicity and antigenicity.
    Puccetti P; Romani L; Taramelli D; Bonmassar E; Fioretti MC
    Int J Tissue React; 1982; 4(3):189-99. PubMed ID: 6183194
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune inhibition of allogeneic lymphoma cells in the peritoneal cavity of mice.
    Fioretti MC; Libarati M; Bonmassar E; Cudkowicz G
    Cancer Res; 1975 Jan; 35(1):30-6. PubMed ID: 1089042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "In vitro" induction of primary cell-mediated immune response to drug-altered lymphoma cells.
    Romani L; Fioretti MC
    Boll Soc Ital Biol Sper; 1978 Oct; 54(20):1943-9. PubMed ID: 753282
    [No Abstract]   [Full Text] [Related]  

  • 5. Cell-mediated immunity to Friend virus-induced leukemia.
    Ting CC; Shiu G; Rodrigues D; Herberman RB
    Cancer Res; 1974 Jul; 34(7):1684-7. PubMed ID: 4134674
    [No Abstract]   [Full Text] [Related]  

  • 6. Secondary cytotoxic response in vitro against Moloney lymphoma cells antigenically altered by drug treatment in vivo.
    Santoni A; Kinney Y; Goldin A
    J Natl Cancer Inst; 1978 Jan; 60(1):109-12. PubMed ID: 146746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo.
    Riccardi C; Fioretti MC; Giampietri A; Puccetti P; Goldin A
    Transplantation; 1978 Feb; 25(2):63-8. PubMed ID: 146282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo.
    Romani L; Fioretti MC; Bonmassar E
    Transplantation; 1979 Sep; 28(3):218-22. PubMed ID: 494379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake of 5-iododeoxyuridine as a measure of tumor growth and tumor inhibition.
    Bonmassar E; Houchens DP; Fioretti MC; Goldin A
    Chemotherapy; 1975; 21(6):321-9. PubMed ID: 1183242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice.
    Parmiani G; Sensi ML; Carbone G; Colombo M; Pierotti M; Ballinari D; Hilgers J; Hilkens J
    Int J Cancer; 1982 Mar; 29(3):323-32. PubMed ID: 7068280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens.
    Romani L; Grohmann U; Fazioli F; Puccetti P; Mage MG; Fioretti MC
    Cancer Immunol Immunother; 1988; 26(1):48-54. PubMed ID: 3257903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of inhibition of tumour cell DNA synthesis by immune cells in Gross virus induced leukemia.
    Finklestein JZ; Byfield J; Tittle K; Imagawa DT
    Rev Eur Etud Clin Biol; 1972 Mar; 17(3):287-92. PubMed ID: 5053619
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo lysis of L5178Y cells in the establishment of the tumor-dormant state in DBA/2 mice.
    Wheelock EF; Weinhold KJ; Ingenito GG; Goldstein LT
    J Immunol; 1980 Apr; 124(4):1642-7. PubMed ID: 7365237
    [No Abstract]   [Full Text] [Related]  

  • 14. Antigenic modulation as a mechanism for tumor escape from immune destruction: identification of modulation-positive and modulation-negative mouse lymphomas with xenoantisera to murine leukemia virus gp70.
    Stackpole CW; Cremona P; Leonard C; Stremmel P
    J Immunol; 1980 Oct; 125(4):1715-23. PubMed ID: 6251136
    [No Abstract]   [Full Text] [Related]  

  • 15. Antigenic properties of lymphoma sublines derived from a drug-treated immunogenic L5178Y leukemia.
    Fioretti MC; Romani L; Taramelli D; Goldin A
    Transplantation; 1978 Dec; 26(6):449-51. PubMed ID: 734739
    [No Abstract]   [Full Text] [Related]  

  • 16. Cell-mediated response to a mouse leukemic subline antigenically altered following drug treatment in vivo.
    Nicolin A; Bini A; Franco P; Goldin A
    Cancer Chemother Rep; 1974; 58(3):325-30. PubMed ID: 4841716
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
    Houchens DP; Bonmassar E; Gaston MR; Kende M; Goldin A
    Cancer Res; 1976 Apr; 36(4):1347-52. PubMed ID: 1260759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of host defense merchanisms in the antitumor activity of adriamycin and daunomycin in mice.
    Mantovani A; Polentarutti N; Luini W; Peri G; Spreafico F
    J Natl Cancer Inst; 1979 Jul; 63(1):61-6. PubMed ID: 286835
    [No Abstract]   [Full Text] [Related]  

  • 19. Serologic analysis of tumor-associated surface antigens on a Moloney leukemia virus-induced lymphoma, MBL-2.
    Ng AK; McIntire R; Holden HT; Herberman RB
    J Immunol; 1978 Sep; 121(3):856-62. PubMed ID: 690439
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies of H-2 restriction in cell-mediated cytotoxicity and transplantation immunity to Leukemia-associated antigens.
    Ting CC; Law LW
    J Immunol; 1977 Apr; 118(4):1259-64. PubMed ID: 191534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.